Axsome Therapeutics Reports Second Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 08/09/21
Axsome Therapeutics Announces AXS-05 Achieves Primary and Key Secondary Endpoints in the MERIT Phase 2 Trial in Treatment Resistant DepressionGlobeNewsWire • 08/09/21
Axsome Therapeutics to Report Second Quarter 2021 Financial Results on August 9, 2021GlobeNewsWire • 07/15/21
Axsome Therapeutics Targets Submission Of US Application For Fibromyalgia Candidate By 2022Benzinga • 06/15/21
Axsome Therapeutics, Inc. (AXSM) CEO Herriot Tabuteau on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/10/21
Axsome Therapeutics Reports First Quarter 2021 Financial Results and Provides Business UpdateGlobeNewsWire • 05/10/21
Why Earnings Season Could Be Great for Axsome Therapeutics (AXSM)Zacks Investment Research • 05/07/21
Axsome Therapeutics Joins Mental Health America and other Advocacy Organizations in Raising Awareness and Providing Support for Mental Health During Mental Health MonthGlobeNewsWire • 05/07/21
Why Voyager Therapeutics, uniQure, Axsome, Reviva Pharma and Crispr Are Moving TodayBenzinga • 04/26/21
FDA Begins Priority Review of Axsome Therapeutics' Potential New Depression DrugThe Motley Fool • 04/26/21